Core Viewpoint - The article highlights the significance of the New Fortune Gold Medal Secretary selection in the Chinese capital market, emphasizing the role of outstanding secretaries in enhancing corporate governance and investor relations, thus contributing to high-quality market development [1]. Group 1: Company Overview - Kaineng Health has been focusing on its core water purification business while advancing a globalization strategy, optimizing product structure, and improving operational efficiency to achieve growth in scale, quality, and profitability [1][4]. - Xu Yanmao, the company secretary, has a strong investment banking background and plays a crucial role in connecting the capital market with corporate development [1][4]. Group 2: Governance Innovation - Xu Yanmao promotes a long-term value creation approach, establishing a stable, efficient, and transparent market value management system, thereby enhancing corporate governance [8]. - The governance structure has been improved through systematic enhancements of the "three meetings" process, ensuring compliance and efficiency in shareholder meetings, board meetings, and supervisory meetings [9]. - In response to regulatory changes, Xu led the revision of ten core systems, including ESG management and related party transaction decision-making, transitioning governance from reactive to proactive [9]. Group 3: Investor Relations - Xu demonstrates effective communication strategies by engaging with well-known sell-side institutions and organizing regular performance briefings, thereby accurately conveying the company's strategic value [10]. - The company has achieved modernization in governance and an increase in total market value, receiving multiple accolades such as "National Green Factory" and "Specialized and New Little Giant" [10]. Group 4: Capital Operations and Strategic Drive - Xu promotes a shift in market value management from a tool-based approach to a value-driven strategy, focusing on maximizing company value through systematic institutional development and capital project execution [12]. - The company is enhancing its capital structure through various mechanisms, including convertible bonds and shareholder return policies, becoming the first in its sector to implement special dividends post-dividend policy reform [12]. - Kaineng Health is expanding its dual-driven model of "water purification + cells," focusing on technological innovation and smart manufacturing while exploring opportunities in the health sector through its investment in Yuaneng Group [13]. Group 5: Globalization Efforts - The company is accelerating its global expansion, establishing a presence in over 100 countries and regions, and is recognized as one of the few Chinese water purification equipment companies with a global distribution network [15]. - The management team is committed to transforming Kaineng into a multinational corporation in the water purification industry through strategic capital operations and local production [15].

关于公司控股股东部分股份解除质押的公告 证券代码：002172 证券简称：澳洋健康 公告编号：2025-21 江苏澳洋健康产业股份有限公司（以下简称"澳洋健康"或"公司"）近日接到 控股股东澳洋集团有限公司（以下简称"澳洋集团"）的通知，获悉澳洋集团所持 有公司的部分股份解除质押，具体事项如下： 一、控股股东股份解除质押的基本情况 | 股东名称 | 是否为控 股股东或 第一大股 | 本次解除质押 | 占其所持 | 占公司总 | 质押起始日 | 解除质押日 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 东及其一 | 股数（股） | 股份比例 | 股本比例 | | | | | | 致行动人 | | | | | | | | | | | | | | | 新疆玛纳斯 | | 澳洋集团 | 是 | 22,300,000 | 9.48% | 2.91% | 2022-01-28 | 2025-05-13 | 农村商业银 | | 有限公司 | | | | | | | 行股份有限 | | | | | | | | | 公司 | | 合计 | | 22, ...

澳洋健康（002172）公告，公司控股股东澳洋集团所持有的2230万股股份解除质押，占其所持股份比例 的9.48%，占公司总股本比例的2.91%。此次解除质押的股份于2022年1月28日质押，于2025年5月13日 解除质押，质权人为新疆玛纳斯农村商业银行股份有限公司。截至公告披露日，控股股东及其一致行动 人累计质押股份数量占其所持公司股份数量比例为37.41%。 ...

| 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 300740 | 水羊股 份 | 7.34 | 11.92 | 1365.96 | 2.37 | | 002762 | *ST金 比 | 1.87 | 6.12 | 764.00 | 12.09 | | 002172 | 澳洋健 康 | -1.64 | 5.20 | 490.76 | 3.40 | | 600572 | 康恩贝 | 0.00 | 0.81 | 453.06 | 4.92 | | 002566 | 益盛药 业 | 0.56 | 2.84 | 449.27 | 9.45 | | 000516 | 国际医 学 | -2.10 | 1.02 | 173.25 | 1.49 | | 603139 | 康惠制 | -1.57 | 1.79 | -62.03 | -1.77 | | | 药 | | | | | | 000615 | *ST 美 | 0.63 | 1.59 ...

2024 年年度股东大会会议决议公告 证券代码：002172 证券简称：澳洋健康 公告编号：2025-20 江苏澳洋健康产业股份有限公司 2024 年年度股东大会会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确、完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、 特别提示 1、本次股东大会召开期间没有发生增加、否决或变更议案的情况； 2、本次股东大会未涉及变更前次股东大会决议的情况； 3、本次股东大会采取现场投票、网络投票相结合的方式召开。 二、 会议召开的情况 1、 召开时间：2025 年 5 月 7 日下午 14:00； 2、 召开地点：张家港市杨舍镇塘市澳洋国际大厦 A 座会议室； 3、 召开方式：本次股东大会采取现场投票与网络投票相结合的方式； 4、 召集人：江苏澳洋健康产业股份有限公司董事会； 5、 主持人：董事长沈学如； 6、 会议的召开符合《公司法》《股票上市规则》及《公司章程》的相关规 定。 三、 会议的出席情况 1、出席会议股东的总体情况： 通过现场和网络投票的股东 313 人，代表股份 244,680,981 股，占上市公司 总股份的 31.9539%％。 2、现场会议股东出 ...

根据《中华人民共和国公司法》《中华人民共和国证券法》和中国证券监督 管理委员会《上市公司股东会规则》等法律、法规和规范性文件以及《江苏澳洋 健康产业股份有限公司章程》（以下简称"《公司章程》"）的规定，江苏世纪 同仁律师事务所（以下简称"本所"）接受江苏澳洋健康产业股份有限公司（以 下简称"贵公司"）的委托，指派本所律师出席贵公司 2024 年年度股东大会，并 就本次股东大会的召集、召开程序、出席会议人员资格、召集人资格、表决程序 以及表决结果的合法有效性等事项出具法律意见。 为出具本法律意见书，本所律师对本次股东大会所涉及的有关事项进行了审 查，查阅了相关会议文件，并对有关问题进行了必要的核查和验证。 本所律师同意将本法律意见书随贵公司本次股东大会决议一并公告，并依法 对本法律意见书承担相应的责任。 本所律师根据相关法律、法规和规范性文件的要求，按照律师行业公认的业 务标准、道德规范和勤勉尽责精神，出具法律意见如下： 澳洋健康 2024 年年度股东大会 法律意见书 江苏世纪同仁律师事务所关于 江苏澳洋健康产业股份有限公司 2024 年年度股东大会的法律意见书 致：江苏澳洋健康产业股份有限公司 一、关于本次股 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥452,119,969.79, a decrease of 22.27% compared to ¥581,691,001.68 in the same period last year[3] - The net profit attributable to shareholders was ¥18,499,176.25, down 39.82% from ¥30,739,368.29 year-on-year[3] - Basic and diluted earnings per share decreased by 50.00%, from ¥0.04 to ¥0.02[3] - The company reported a net loss of CNY 1,914,023,406.35, an improvement from a net loss of CNY 1,932,522,582.60 in the previous period[14] - The net profit for the current period is 18,855,007.11, a decrease of 39.5% compared to 31,137,825.62 in the previous period[18] - Operating profit for the current period is 23,561,806.87, down 34.4% from 35,955,833.29 in the previous period[18] - Total profit for the current period is 24,196,720.51, a decline of 37.7% compared to 38,810,915.19 in the previous period[18] - The company reported sales revenue of 309,625,785.38, a decrease of 39.2% from 509,722,231.34 in the previous period[20] Cash Flow and Liquidity - The net cash flow from operating activities was -¥179,940,705.79, an improvement of 15.13% compared to -¥212,015,808.16 in the previous year[3] - Cash flow from operating activities shows a net outflow of -179,940,705.79, improving from -212,015,808.16 in the previous period[20] - Cash and cash equivalents decreased by 45.95% year-on-year, primarily due to increased restricted cash for acceptance bills[8] - Cash and cash equivalents at the end of the period amounted to CNY 461,455,379.42, a decrease of 11.5% from CNY 521,489,938.85 at the beginning of the period[12] - Cash and cash equivalents at the end of the period amount to 226,341,631.14, down from 418,744,268.63 in the previous period[21] - The company’s total cash inflow from financing activities is 665,407,900.61, slightly down from 671,846,211.49 in the previous period[21] - The company’s total cash outflow from investing activities is 16,332,745.34, compared to 15,788,314.50 in the previous period[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,049,816,701.24, a slight decrease of 0.06% from ¥2,051,047,821.36 at the end of the previous year[3] - Total assets decreased slightly to CNY 2,049,816,701.24 from CNY 2,051,047,821.36, a decline of 0.1%[14] - Total liabilities decreased to CNY 1,915,731,197.13 from CNY 1,935,817,324.36, a reduction of 1.0%[14] - The company's equity attributable to shareholders increased to CNY 153,021,601.65 from CNY 134,522,425.40, an increase of 13.7%[14] - Short-term borrowings decreased to CNY 682,185,039.73 from CNY 704,846,127.84, a decline of 3.2%[13] Operational Metrics - The company reported a 39.26% decrease in cash received from sales of goods and services compared to the previous year[8] - Total operating costs for the current period were CNY 428,104,319.98, down 20.9% from CNY 541,279,571.75 in the previous period[16] - Accounts receivable increased to CNY 319,682,576.81 from CNY 291,583,598.00, reflecting a growth of 9.6%[12] - Inventory rose to CNY 167,097,279.41, up 11.8% from CNY 149,474,811.92[13] - The company experienced a 333.47% increase in financial expenses year-on-year, attributed to reduced interest income from maturing deposits[7] - The company incurred financial expenses of 7,562,338.98, compared to a financial income of -3,239,154.66 in the previous period[18] - The weighted average return on equity was 12.87%, down 15.27% from 28.14% in the same period last year[3] - The number of ordinary shareholders at the end of the reporting period was 53,714[9]

A股医疗服务板块走低，三博脑科跌超12%，华南生物跌停，万邦医药跌超5%，澳洋健康、通策医疗等 跌幅居前。 ...

智通财经4月21日电，可靠股份20CM涨停，澳洋健康、安正时尚、阳光乳业、拉芳家化涨停，百亚股 份、嘉和美康、唯科科技、日播时尚、麦趣尔等多股涨超5%。消息面上，近期多地出台生育补贴政 策，其中辽宁表示拟加强生育养育保障，落实育儿补贴制度。 婴童概念股震荡走强 可靠股份20CM涨停 ...

Policy Developments - The National Medical Products Administration (NMPA) approved the registration of 308 medical device products as of March 2025, including 248 domestic Class III medical devices, 34 imported Class III medical devices, 19 imported Class II medical devices, and 7 medical devices from Hong Kong, Macau, and Taiwan [1] Drug Approvals - Chengdu Saijing Bio's ursodeoxycholic acid oral suspension has been approved as the first domestic generic Class 3.1 new drug for treating cystic fibrosis-associated liver disease (CFALD), filling a gap in the market for this indication [2] - Kowa Company's pemafibrate tablets have been approved in China for the treatment of dyslipidemia [3] - Merck Sharp & Dohme (MSD) announced that its nine-valent HPV vaccine has received approval for male use in China, targeting males aged 16-26, enhancing public awareness of HPV infections in men [5] Capital Market - Zhongjie Chaorun completed a Pre-A round financing of several million yuan, primarily for clinical trials of its artificial meniscus implant and commercialization of its innovative meniscus suturing device [4] Financial Reports - Aoyang Health reported a 2024 revenue of 2.01 billion yuan, a year-on-year decrease of 7.54%, with a net profit of 40.56 million yuan, down 18.36% [6] - Novogene announced a total revenue of 2.111 billion yuan for 2024, a year-on-year increase of 5.45%, with a net profit of 197 million yuan, up 10.52% [7] - Tianyi Medical reported a revenue of 419 million yuan for 2024, a year-on-year increase of 9.98%, but a net loss of 744,000 yuan [8] - Luoxin Pharmaceutical disclosed a net loss of 962 million yuan for 2024, despite a revenue increase of 11.99% to 2.647 billion yuan [9] - Dongxing Medical reported a revenue of approximately 435 million yuan for 2024, a slight increase of 0.4%, with a net profit of about 97.42 million yuan, up 0.21% [10] Public Sentiment - Xinbang Pharmaceutical announced the resignation of independent director Zhou Jun, with the company reporting a revenue of 6.032 billion yuan for 2024, down 6.63%, and a net profit of 101 million yuan, down 64.70% [11] - Shuangcheng Pharmaceutical warned of potential delisting risk due to expected negative net profit and revenue below 300 million yuan for 2024 [12]